CD160
CD160 molecule
Summary
CD160 is an 27 kDa glycoprotein which was initially identified with the monoclonal antibody BY55. Its expression is tightly associated with peripheral blood NK cells and CD8 T lymphocytes with cytolytic effector activity. The cDNA sequence of CD160 predicts a cysteine-rich, glycosylphosphatidylinositol-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to KIR2DL4 molecule. CD160 is expressed at the cell surface as a tightly disulfide-linked multimer. RNA blot analysis revealed CD160 mRNAs of 1.5 and 1.6 kb whose expression was highly restricted to circulating NK and T cells, spleen and small intestine. Within NK cells CD160 is expressed by CD56dimCD16+ cells whereas among circulating T cells its expression is mainly restricted to TCRgd bearing cells and to TCRab+CD8brightCD95+CD56+CD28-CD27-cells. In tissues, CD160 is expressed on all intestinal intraepithelial lymphocytes. CD160 shows a broad specificity for binding to both classical and nonclassical MHC class I molecules. [provided by RefSeq, Jul 2008]
Known Variants9 total
| rsid | Position (GRCh37) | Alleles | Class | ClinVar |
|---|---|---|---|---|
| rs879994994 | 1:145,699,039 | A/T | — | uncertain significance |
| rs200857991 | 1:145,704,053 | G/A | — | uncertain significance |
| rs1380211387 | 1:145,704,067 | T/C | — | uncertain significance |
| rs145560737 | 1:145,704,100 | T/C | — | uncertain significance |
| rs148311134 | 1:145,704,167 | C/T | — | benign |
| rs1552172 | 1:145,704,759 | T/A | intron variant | — |
| rs782061205 | 1:145,706,704 | C/T | — | uncertain significance |
| rs72704264 | 1:145,713,305 | G/C | intron variant | — |
| rs744877 | 1:145,714,376 | G/C | — | — |
Gene information from NCBI Gene. Variant classifications from ClinVar.